-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, Suzhou Runxin Biotech Co., Ltd. (hereinafter known as Runxin Bio) announced that the company in the new drug RX108 treatment of relapsed glioblastoma phase 2 clinical study recently completed the first patient administration at Fudan University affiliated Huashan Hospital.
RX108 is a type of innovative drug with global intellectual property rights developed by Runxin Bio, is a novel Na-K-ATP enzyme inhibitor, with a "one-goal multi-point" mechanism, can play an anti-tumor role through a variety of ways.
currently, the drug is conducting a number of clinical studies on different solid tumors in China and the United States.
is known that this completed clinical study of the first patient administration is a single-arm, open, multi-center Phase 2 clinical trial designed to evaluate the effectiveness and safety of patients with glioblastoma who have progressed or relapsed in RX108 after standard treatment.
public data show that brain tumors account for 1.4% of all tumors, about 300,000 new people are added globally each year, and about 100,000 new in China each year.
glioblastoma (GBM) is the most aggressive type of brain tumor.
Note: The original text has a limitation.